Iran private hospitals face unpaid insurance bills

Hospital managers say arrears from public and supplementary insurers have gone unpaid for the entire 1403 Iranian calendar year, with one large provincial hospital saying it has contracts with about 35 insurers and welfare bodies yet none has settled its dues. Debt from Day Insurance and Dana Insurance was described as especially large. Another hospital with more than 1,200 medical and administrative staff said inflation has made it difficult to replace consumed drugs and equipment, noting that the price of Ringer’s solution has risen 600% over three years.

The pressure is not limited to a few line items. Insulin and widely used blood-pressure medicines have risen as much as 50% in the past month, according to the report, while some drug prices have climbed as much as 380% over recent months. One private hospital said it created a separate unit just to reprice medicines because costs change every day even though treatment tariffs are set annually. That mismatch between regulated reimbursement and market pricing is exactly the kind of squeeze that can turn a seemingly stable business into a liquidity problem.

The financial stress is showing up across the wider health-care chain. Iran Health Insurance head Mohammadmehdi Nassehi said inflation and higher expenses had created a mismatch between revenues and costs from the second half of 1403, while also citing 42 trillion tomans of health ministry debt to the insurer. Social Security Organization payments of 5 trillion tomans to private pharmacies and treatment centers may provide temporary relief, but the disclosure does not show how much arrears remain. In other words, there is still no clear sign the system has been recapitalized enough to restore normal cash flow.

For patients, the consequences are even more immediate. Reports say some retirees are unable to find medicines at Social Security facilities and are being forced to shop elsewhere. Some commonly used injectable drugs have also been removed from outpatient insurance coverage, adding out-of-pocket expense at a time when many pensioners are already rationing treatment or skipping visits altogether. That is bad economics and bad investing, because a health system that pushes costs onto patients eventually suppresses utilization, harms outcomes and raises political pressure for intervention.

This is why the problem goes beyond hospital accounting. Currency weakness, sanctions and imported-medical-supply dependence are turning a reimbursement issue into a system-wide affordability crisis. If the exchange rate keeps rising and imported medicines remain difficult to source, hospitals will face higher working-capital needs just as insurers struggle to pay old bills. The result is a vicious cycle: more debt, less inventory, and weaker access to care.

For investors, the long-term lesson is simple. In any health-care system, the strongest operators are the ones with pricing power, reliable reimbursement and enough cash flow to ride out inflation. Iran’s private hospitals appear to have none of those advantages right now. Until insurers clear arrears and tariffs move faster than costs, the sector looks likely to remain under pressure, with patients, not institutions, paying the price.